Percheron Therapeutics has announced that it will investigate avicursen (ATL1102) in other indications besides Duchenne muscular dystrophy (DMD) following disappointing Phase IIb results last month.

Percheron Capital is a private equity firm focused on partnering with exceptional teams to build market-leading essential services businesses. The firm’s purpose is to support high-quality ...

Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Percheron Therapeutics has reported a significant change in its substantial shareholding, as Platinum Investment ...

DMD occurs in approximately one in every 3,500 male births. Credit: Dan76 / Shutterstock. Percheron Therapeutics has announced that it will investigate avicursen (ATL1102) in other indications besides ...

Percheron Therapeutics board addresses shareholders following failed phase 2b trial EBR’s US FDA manufacturing pre-approval inspection scheduled to start January 14 as share price rockets Regis ...